We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Israel' Teva Pharmaceutical has announced May 28 that the U.S. FDA has granted tentative approval for the company's abbreviated new drug application (ANDA) to market its generic version of Merck's antihypertensive agent Cozaar (losartan potassium) tablets, in strengths of 25, 50 and 100 mg.
New Jersey-based Alpharma has reached an agreement with China's Zhejiang Hisun Pharmaceutical that could double the company's capacity to manufacture one of its major active pharmaceutical ingredients (APIs), Vancomycin, subject to the receipt of the required regulatory approvals.
Japan-based drugmakers Tanabe Seiyaku and Maruho have entered into a licensing agreement for phosphodiesterase 4 (PDE4) inhibitor, a drug candidate for treating skin diseases.
A flaw in the existing Drug Price Control Order (DPCO), which ignores the 'Superior Quality' parameter while calculating the ceiling price of drugs, may deprive patients from accessing 'best' medicines available in the country.
Some blood pressure drugs previously thought to be safe when taken early in pregnancy now appear to substantially raise the risk of major birth defects, doctors say.
The Empowered Group of Ministers on Biotechnology has cleared proposals to relax norms for the biotechnology sector in agriculture and health in order to encourage entrepreneurship, innovation and greater participation from small investors, Union Minister for Science and Technology Kapil Sibal said here on Wednesday.
Swiss Medica, Inc. announced today that international recognition continues to grow for its patented, all natural and clinically tested product O24 Fibromyalgia, with official approval by the Fibromyalgia Support Group Surrey & Sussex in the United Kingdom.
Alpharma Inc. today announced that it had reached an agreement with Zhejiang Hisun Pharmaceutical Co., Ltd ("Hisun") that, over the next several years, will double the company's capacity to manufacture one of its major active pharmaceutical ingredients ("API"), Vancomycin, subject to the receipt of the required regulatory approvals. Vancomycin is the treatment of choice for severe gram positive hospital infections.